~~<i id='DBC904E549'><strike id='DBC904E549'><tt id='DBC904E549'><pre id='DBC904E549'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：knowledge 2025-09-29 09:07:00 Page View：618

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Stanford president's case begs question: Who takes blame?
Next article： Anesthesiologist group: stop taking Ozempic before surgery

explore

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Indian pharmaceutical industry in denial over drug

AchemistworksatapharmaceuticalmanufacturingplantontheoutskirtsofMumbai.Drugmakersinthecountryhavecom

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

STAT Summit: The economic case for universal basic health care

MITeconomistAmyFinkelsteinchatswithSTAT'sBobHermanatthe2023STATSummit.STATFixingtheU.S.healthcaresys